Browse EV MemProt Atlas
- Frequency:
- literature support frequency.
- EVMP score:
annotation confidence score.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40
| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| FLNC | Q14315 | Filamin-C (FLN-C) (FLNc) (ABP-280-like protein) (ABP-L) (Actin-binding-like protein) (Filamin-2) (Gamma-filamin) | Disease related genesHuman disease related genesPlasma proteinsPotential drug targetsPredicted intracellular proteinsTransporters | Adhesion and uptake mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.50 | ||||
| FLOT2 | Q14254 | Flotillin-2 (Epidermal surface antigen) (ESA) (Membrane component chromosome 17 surface marker 1) | Plasma proteinsPredicted intracellular proteins | Adhesion and uptake mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation | 1 | 0.50 | ||||
| FLRT3 | Q9NZU0 | Leucine-rich repeat transmembrane protein FLRT3 (Fibronectin-like domain-containing leucine-rich transmembrane protein 3) | Disease related genesHuman disease related genesPotential drug targetsPredicted membrane proteinsTransporters | 1 | Adhesion and uptake mediationReceptor-signaling mediation | 1 | 0.50 | |||
| FMNL3 | Q8IVF7 | Formin-like protein 3 (Formin homology 2 domain-containing protein 3) (WW domain-binding protein 3) (WBP-3) | Predicted intracellular proteins | Receptor-signaling mediation | 1 | 0.50 | ||||
| FR1L5 | A0AVI2 | Fer-1-like protein 5 | 1 | Fusion and delivery mediation | 1 | 0.50 | ||||
| FR1L6 | Q2WGJ9 | Fer-1-like protein 6 | Plasma proteinsPredicted membrane proteins | 1 | Other mediation | 1 | 0.50 | |||
| FRMD8 | Q9BZ67 | FERM domain-containing protein 8 (Band4.1 inhibitor LRP interactor) (Bili) (iRhom tail-associated protein) (iTAP) | Predicted intracellular proteins | Receptor-signaling mediation | 1 | 0.50 | ||||
| FUT2 | Q10981 | Galactoside alpha-(1,2)-fucosyltransferase 2 (Alpha(1,2)FT 2) (Fucosyltransferase 2) (GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase 2) (SE2) (Secretor blood group alpha-2-fucosyltransferase) (Secretor factor) (Se) (Type 1 galactoside alpha-(1,2)-fucosyltransferase FUT2) (EC 2.4.1.69) (Type 2 galactoside alpha-(1,2)-fucosyltransferase FUT2) (EC 2.4.1.344) | Blood group antigen proteinsEnzymesMetabolic proteinsPredicted membrane proteins | 1 | Metabolism mediationReceptor-signaling mediation | 1 | 0.50 | |||
| GALR1 | P47211 | Galanin receptor type 1 (GAL1-R) (GALR-1) | 7 | Fusion and delivery mediationReceptor-signaling mediation | 1 | 0.50 | ||||
| GAPD1 | Q14C86 | GTPase-activating protein and VPS9 domain-containing protein 1 (GAPex-5) (Rab5-activating protein 6) | Predicted intracellular proteins | Fusion and delivery mediation | 1 | 0.50 | ||||
| GAPT | Q8N292 | Protein GAPT (GRB2-binding adapter protein, transmembrane) (Growth factor receptor-bound protein 2-binding adapter protein, transmembrane) | Predicted intracellular proteins | 1 | Immune mediation | 1 | 0.50 | |||
| GBRA1 | P14867 | Gamma-aminobutyric acid receptor subunit alpha-1 (GABA(A) receptor subunit alpha-1) (GABAAR subunit alpha-1) | Disease related genesFDA approved drug targetsHuman disease related genesPredicted intracellular proteinsPredicted membrane proteinsTransporters | 4 | Acute respiratory distress syndromeAnxiety disorderChronic insomniaChronic painCorneal diseaseCystitisDepressionEpilepsy/seizureFemale pelvic painHeadacheIndeterminate colitisInsomniaLiver vascular disorderMalariaMental/behavioural/neurodevelopmental disorderPostoperative inflammationStatus epilepticusTonus and reflex abnormalityTremor-related disorder | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.50 | ||
| GBRA2 | P47869 | Gamma-aminobutyric acid receptor subunit alpha-2 (GABA(A) receptor subunit alpha-2) (GABAAR subunit alpha-2) | 4 | General pain disorderIndeterminate colitisIntentional self-harmPostoperative inflammationSubstance abuse | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.50 | |||
| GBRA3 | P34903 | Gamma-aminobutyric acid receptor subunit alpha-3 (GABA(A) receptor subunit alpha-3) (GABAAR subunit alpha-3) | FDA approved drug targetsPredicted membrane proteinsTransporters | 4 | Anxiety disorderIndeterminate colitisIntentional self-harmPostoperative inflammationSchizophreniaSleep-wake disorder | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.50 | ||
| GBRA5 | P31644 | Gamma-aminobutyric acid receptor subunit alpha-5 (GABA(A) receptor subunit alpha-5) (GABAAR subunit alpha-5) | 4 | Adaptive immunity immunodeficiencyAlzheimer diseaseAutism spectrum disorderIndeterminate colitisIntentional self-harmMild neurocognitive disorderPostoperative inflammationSex development malformative disorder | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.50 | |||
| GBRG1 | Q8N1C3 | Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1) (GABAAR subunit gamma-1) | FDA approved drug targetsPredicted membrane proteins | 4 | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.50 | |||
| GBRG3 | Q99928 | Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3) (GABAAR subunit gamma-3) | FDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins | 4 | Alzheimer diseaseAnxiety disorderCorneal diseaseDepressionEpilepsy/seizureFemale pelvic painFragile X chromosomeGeneral pain disorderInsomniaIntentional self-harmIschaemic/haemorrhagic strokeLabour/delivery anaesthesia complicationMental/behavioural/neurodevelopmental disorderMood/affect symptomNeurodegenerative disorderPainPanic disorderParkinsonismPostoperative inflammationStatus epilepticusSubstance abuseTremor-related disorder | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.50 | ||
| GDIB | P50395 | Rab GDP dissociation inhibitor beta (Rab GDI beta) (Guanosine diphosphate dissociation inhibitor 2) (GDI-2) | Plasma proteinsPredicted intracellular proteins | Adhesion and uptake mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation | 1 | 0.50 | ||||
| GFRA2 | O00451 | GDNF family receptor alpha-2 (GDNF receptor alpha-2) (GDNFR-alpha-2) (GFR-alpha-2) (GDNF receptor beta) (GDNFR-beta) (Neurturin receptor alpha) (NRTNR-alpha) (NTNR-alpha) (RET ligand 2) (TGF-beta-related neurotrophic factor receptor 2) | Predicted intracellular proteins | Fusion and delivery mediationReceptor-signaling mediation | 1 | 0.50 | ||||
| GGTA1 | Q4G0N0 | Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase (Glycoprotein alpha-galactosyltransferase 1 pseudogene) | Predicted intracellular proteins | 1 | Other mediation | 1 | 0.50 | |||
| GHR | P10912 | Growth hormone receptor (GH receptor) (Somatotropin receptor) [Cleaved into: Growth hormone-binding protein (GH-binding protein) (GHBP) (Serum-binding protein)] | Disease related genesFDA approved drug targetsHuman disease related genesPredicted membrane proteinsPredicted secreted proteins | 1 | COVID-19MalariaMiddle East Respiratory SyndromeSevere acute respiratory syndromeBinge eating disorderObesityPituitary gland disorderShort stature | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation | 1 | 0.50 | ||
| GINM1 | Q9NU53 | Glycoprotein integral membrane protein 1 | Predicted intracellular proteinsPredicted membrane proteins | 1 | Other mediation | 1 | 0.50 | |||
| GLP1R | P43220 | Glucagon-like peptide 1 receptor (GLP-1 receptor) (GLP-1-R) (GLP-1R) | 7 | Acute diabete complicationAlzheimer diseaseCardiovascular diseaseDiabetes mellitusDyspepsiaHypo-glycaemiaIntracranial injuryIrritable bowel syndromeNon-alcoholic fatty liver diseaseObesityPancreatic internal secretion disorderParkinsonismType 2 diabetes mellitusType-1/2 diabete | Clinical-translation mediationFusion and delivery mediationMetabolism mediationReceptor-signaling mediation | 1 | 0.50 | |||
| GLP2R | O95838 | Glucagon-like peptide 2 receptor (GLP-2 receptor) (GLP-2-R) (GLP-2R) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | Bowel habit changeDigestive system diseaseIndeterminate colitisLow bone mass disorderNeonatal malabsorption syndrome | Clinical-translation mediationReceptor-signaling mediation | 1 | 0.50 | ||
| GLPA | P02724 | Glycophorin-A (MN sialoglycoprotein) (PAS-2) (Sialoglycoprotein alpha) (CD antigen CD235a) | Blood group antigen proteinsCD markersPredicted membrane proteinsTransporters | 1 | Immune mediation | 1 | 0.50 |